Companies Dominating the Recombinant Proteins Landscape
- Thermo Fisher Scientific Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck KGaA
- Lonza Group AG
- GenScript Biotech Corporation
- AbbVie Inc.
- Amgen Inc.
- Roche Holdings Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
Browse Key Market Insights with Data Illustration:
In the News
-
Merck KGaA: Merck announced that it had signed an agreement to acquire AmpTec, a leading provider of high-quality RNA and mRNA for research and commercial applications. The acquisition will strengthen Merck's capabilities in the field of mRNA-based therapeutics and vaccines.
-
Roche Holdings Inc.: Roche announced that it had received approval from the US Food and Drug Administration (FDA) for its recombinant protein Hemlibra, for the treatment of hemophilia A in patients without factor VIII inhibitors. Hemlibra is a bispecific antibody designed to bring together factors IXa and X, which are needed to activate the natural coagulation cascade and restore the blood clotting process.
